Illumina provides access to the flat-genome ("sequence"). But genome is NOT flat. It is folded in a sophisticated manner in its native context in situ with cells. Changes to the spatial context of in situ DNA leads to disease.
San Diego, CA, USA
One Liner
One Liner
Illumina provides access to the flat-genome ("sequence"). But genome is NOT flat. It is folded in a sophisticated manner in its native context in situ with cells. Changes to the spatial context of in situ DNA leads to disease.
What Problem We are Solving
Problem
The Genome is being assumed to be flat / linear. It is NOT. Changes to the spatial context of the in situ DNA leads to disease. We have multiple lines of evidence – nearly 100 customer publications. We will serve CLIA labs as an LDT / Dx to diagnose undiagnosed tumors. We will serve biopharma to find new biomarkers.
About Us
About Us
We offer end to end workflows. We are a reagent business. The value prop is to offer access to the in situ DNA information.
Business Model
Business Model
High margin reagents
Competitive Advantage
Quote
NYU LDT collaboration and future publication offers us first to market benefit.
Go-To Market Strategy
Business Strategy
We are revenue generating (2021 forecast: $3.5M revenue). For use-case 1 Dx: Our GTM is LDTs. Work with NYU on an LDT, publish the results and replicate. For use case 2, Biopharma: We already have 18 Biopharma customers offering PO in the range of $50K. Our goal is to get larger POs by helping their clinical trials.
We are open to meeting up to grab a coffee, or just to chat.
We would really enjoy your feedback and insight into our venture and would be happy to discuss anything that you are currently working on to see if we can be of service!
Share
Capital
Name
Amount
Amount Raise To Date
N/A
Investment Type
N/A
Valuation
$18.5M
Think a friend might be interested in this?
Enter their email to share it with them!
An end-to-end solution to early stage ventures and the firms that support them.
